<DOC>
	<DOCNO>NCT01855867</DOCNO>
	<brief_summary>The purpose study see anti-HIV medication know Stribild ( elvitegravir/cobicistat/emtricitabine/tenofovir DF ) safe , tolerable acceptable take 28 day , day possible , sexual , exposure Human Immune Deficiency Virus ( HIV ) .</brief_summary>
	<brief_title>HIV Non-Occupational Post-Exposure Prophylaxis</brief_title>
	<detailed_description>Stribild combination 1 integrase strand transfer inhibitor , 1 pharmacokinetic enhancer , 2 nucleos ( ) ide analog HIV-1 reverse transcriptase inhibitor , approve August 2012 , complete treatment regimen HIV-1 infection adult antiretroviral treatment-na√Øve . We propose evaluate safety , tolerability acceptability Stribild give participant age 18 possible sexual exposure HIV-1 . Enrolled participant experienced moderate high risk exposure , outline study protocol , within last 72 hour - per 2005 Center Disease Control Prevention guideline . Participants take one Stribild tablet , mouth , day 28 day . Study staff ass change blood chemistry clinical sign symptom baseline health . Study participation 90 day include HIV testing , STI screening , HIV/STI risk reduction counseling , clinical assessment , blood draw survey design gather knowledge perception HIV post-exposure prophylaxis ( PEP ) HIV pre-exposure prophylaxis ( PrEP ) . Conditional referral continue HIV/STI risk reduction counsel test make risk remain high study termination . In addition , participant connect medical provider risk demonstrate potential need HIV pre-exposure prophylaxis .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Elvitegravir , Cobicistat , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>&gt; Age 18 time first visit . HIV uninfected basis negative HIV Rapid Test Willing able provide write informed consent . Willing able provide adequate locator information . Willing able return study visit . Willing participate study procedure . Biologic woman childbearing potential : Willing use contraception long study medication plus 7 day . Possible sexual exposure HIV1 , recent enough permit receive first dose study medication within 72 hour end exposure . possible exposure could include : 1 . Unprotected anal , vaginal , oral , mucosal ( e.g . conjunctival ) exposure ejaculate partner HIV1 infect high risk HIV infection unknown HIV1 serostatus ( may include protected sexual exposure condom failure , breakage slippage ) ; 2 . Unprotected penile exposure cervicovaginal secretion anorectal secretion partner HIV1 infect high risk HIV infection unknown HIV1 serostatus ( may include protected sexual exposure condom failure , breakage slippage ) An active psychiatric illness active drug alcohol abuse , opinion investigator , could prevent compliance study procedure . Pregnancy and/or Breastfeeding . Biologic woman actively try become pregnant . Acute Chronic Hepatitis B infection , history Acute Chronic Renal Disease , history Creatinine Clearance 70mL/min ( CockcroftGault equation , Actual Weight ) Known intolerance allergy tenofovir DF , emtricitabine , elvitegravir cobicistat Currently take plan take prohibit medication enrol study . Prohibited Medications* Propulsid ( Cisapride ) UroXatral ( Alfuzosin ) Dihydroergotamine Ergotamine Methylergonovine St John 's Wort ( Hypericum perforatum ) Altocor , Altoprev , Mevacor ( Lovastatin ) Zocor ( Simvastatin ) Orap ( Pimozide ) Rifadin , Rimactane ( Rifampin ) Viagra ( Sildenafil dose REVATIO ) Halcion ( Triazolam ) Versed ( Midazolam ) ( administer orally ) Antiretroviral medication use treat prevent HIV infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HIV</keyword>
	<keyword>PEP</keyword>
	<keyword>nPEP</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Post Exposure Prophylaxis</keyword>
	<keyword>exposure HIV</keyword>
	<keyword>HIV prevention</keyword>
</DOC>